Minerva Neurosciences, Inc. - NERV Company Short-Term Debt

Public company logo of minervaneurosciences.com (NERV)

Minerva Neurosciences is pursuing the expansion of roluperidone for the treatment of schizophrenia while awaiting FDA approval. Business growth is driven by new data on patient cognitive functions and a shortage of CNS treatment methods. This chart of current debt obligations illustrates the financial burden, where the latest value is recorded as 0.00. However, regulatory complexities are weakening market positions, necessitating costly research to protect patents.

minervaneurosciences.com (NERV) - Company Current Liabilities from 07/04/2022 to 10/28/2026

Summary analytical data breakdowns for Minerva (NERV)

- price and consensus price forecast:
Price Chart Minerva Neurosciences, Inc.|NERV - Fair Value Consensus
- market capitalization data:
Market Value Minerva Neurosciences, Inc.|NERV - Total Enterprise Value
- book capitalization data:
Net Assets per Single Share Minerva Neurosciences|NERV - Company Net Assets|Market Capitalization to Book Value Ratio minervaneurosciences.com|NERV - Company Total Asset Base
- debt and liquidity data:
Debt to Equity Minerva Neurosciences|NERV - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital Minerva Neurosciences|NERV - Company Cumulative Debt|Debt to Book Capitalization Ratio Minerva Neurosciences, Inc.|NERV - Company Long-Term Loans and Borrowings|Company Current Liabilities Minerva Neurosciences
Fundamental company valuation:NERV Minerva Neurosciences, Inc.
Manufactured product of Minerva

Investors are assessing the financial stability of Minerva Neurosciences (NERV) through the lens of development costs for roluperidone for schizophrenia therapy. By analyzing the company's short-term liability structure, one can track the volume of debt maturing within a year, which is critical for evaluating refinancing and liquidity risks during the creation of a unique drug, providing a real-time assessment of the business's overall solvency.

Competitor analysis

Company Short-Term Debt Biogen (BIIB)|NBIX: Company Short-Term Loans and Borrowings|Company Short-Term Debt RGC|AXSM (Axsome Corp) - Short-Term Debt|Company Short-Term Debt ACAD|Company Current Liabilities xenon-pharma.com|VKTX (Viking Therapeutics, Inc.) - Company Short-Term Debts|Short-Term Debt Volume SUPN (Supernus Pharmaceuticals, Inc.)|CPRX - Company Short-Term Debt|Company Short-Term Indebtedness Denali Corp DNLI|HRMY (Harmony Biosciences) - Company Short-Term Debts|BHVN: Short-Term Debt|Company Short-Term Debt Amylyx Pharmaceuticals, Inc. AMLX|Company Short-Term Loans and Borrowings Trevi Therapeutics Inc|Company Current Liabilities Praxis Medicines|Company Short-Term Debt Anavex Life Sciences Corp|Company Short-Term Debts CBLL|Company Short-Term Debts Prothena Corporation plc PRTA|Company Current Liabilities Alector|Annexon Biosciences - Company Short-Term Loans and Borrowings|Omeros Corp. (OMER) - Company Short-Term Debt|NGNE - Company Short-Term Indebtedness|Company Short-Term Debts ACIU|Short-Term Debt voyagertherapeutics.com|NMRA (Neumora Therapeutics, Inc.) - Company Current Liabilities|Company Short-Term Debts SCLX|Tevogen Bio Holdings, Inc. (TVGN) - Company Short-Term Debt|Company Short-Term Loans and Borrowings ACOG (alphacognition.com)|CGTX: Company Short-Term Debt|inhibikase.com - Short-Term Debt|Company Short-Term Debt SAVA (Cassava Sciences)|ASRT - Short-Term Debt Volume|COYA (coyatherapeutics.com) - Company Short-Term Debts|Vistagen (VTGN) - Company Current Liabilities|OVID: Company Short-Term Debts|Short-Term Debt Volume acumenpharm.com|CervoMed - Company Short-Term Debts|Short-Term Debt ATHE (alteritytherapeutics.com)|CLNN - Company Short-Term Debt|Company Short-Term Indebtedness PepGen Inc PEPG|JUNS: Company Short-Term Debts|RLMD - Company Current Liabilities|Company Short-Term Debts ANVS|GRCE (Grace Therapeutics) - Short-Term Debt|AIFF: Company Short-Term Debt|Short-Term Debt Volume KLTO|Company Short-Term Debt NeuroSense Therapeutics NRSN|Company Short-Term Indebtedness revivapharma.com (RVPH)|MTVA: Company Short-Term Debts|NeurAxis Inc. - Short-Term Debt|Company Short-Term Debt Helius Medical Technologies Inc. (HSDT)|Passage Bio, Inc. (PASG) - Company Short-Term Loans and Borrowings|bionomics.com.au (NEUP) - Company Current Liabilities|ATHA (athira.com) - Company Short-Term Debt|Company Short-Term Debt Addex Therapeutics Ltd (ADXN)|Company Short-Term Indebtedness Alzamend|Cyclerion Therapeutics - Company Short-Term Debts|Short-Term Debt protagenic.com PTIX|Company Current Liabilities KTTA (Pasithea Therapeutics Corp.)|Cortigent Inc - Company Short-Term Debts|Company Short-Term Debt Avenue Therapeutics, Inc. (ATXI)|BCLI: Company Short-Term Loans and Borrowings|Company Short-Term Debt CARA|CHRO (Chromocell) - Short-Term Debt|Company Short-Term Debt ELYM|Company Current Liabilities Intra-Cellular|LBPH (Longboard Pharmaceuticals, Inc.) - Company Short-Term Debts|Short-Term Debt Volume MRNS (Marinus Pharmaceuticals Inc)|NKGN - Company Short-Term Debt|Company Short-Term Indebtedness NeuroBo Pharma NRBO|SAGE (Sage Therapeutics, Inc.) - Company Short-Term Debts|SNPX: Short-Term Debt|Company Short-Term Debt Trevena TRVN|Company Short-Term Loans and Borrowings Vigil Neuroscience, Inc.|Company Current Liabilities Anew Medical, Inc.|Company Short-Term Debt Cerevel Corp